Abstract:338 Background: Active surveillance (AS) is the preferred management for men with NCCN very low or low risk prostate cancer (PCa) and may be considered for select favorable intermediate risk PCa. AS can be associated with significant grade reclassification and progression to treatment, adverse pathology at radical prostatectomy (RP), and need for salvage therapy. Genomic transcriptomic biomarkers have been shown to be prognostic and potentially predictive of treatment response in the locally advanced and metastatic setting. The potential of transcriptomic biomarkers to identify durable AS candidates and elucidate a potential role for molecular systemic therapies remains unclear. We sought to define transcriptomic markers associated with adverse pathologic features among AS-eligible patients who underwent RP. Methods: We retrospectively identified AS-eligible patients at our institution from February 2012 to March 2023 who underwent RP and completed Decipher genomic classifier testing (n=112). AS-eligible was defined as NCCN very low risk to favorable intermediate risk (no more than one intermediate risk factor, GG1 or 2, and <50% cores positive). The primary outcome was adverse pathologic features (APF) at RP, defined as GG3-5, pT3b, or pN1 disease. Associations between APF and previously defined transcriptomic signatures of interest derived from the Decipher GRID (i.e., PAM50, PSC, PTEN, and eleven prognostic signatures) were tested using Mann-Whitney U and Fisher’s exact tests and multivariable logistic regressions adjusted for log2(PSA) and use of MRI. Statistical significance was defined as p<0.05. Results: Of 112 men, 27% (30/112) had very low or low risk PCa and 73.2% (82/112) had favorable intermediate risk PCa. At RP, 28% (31/112) had APF, the majority due to upgrading to GG3-5 (28/31, 90%) and 10% (3/31) due to upgrading and T3b disease (none had pN1 at RP). Men with APF had higher baseline PSA (6.42 ng/mL vs 4.9 ng/mL, p=0.02) and were less likely to have undergone an MRI fusion biopsy for diagnosis (71% vs 90%, p=0.02). NCCN risk group, PSA density, and core positivity were not significantly associated with APF at RP. Seven of eleven previously characterized prognostic gene-based signatures were associated with APF on multivariable analysis. PTEN loss and increased activated tumoral CD4 activity were also significantly associated with APF. Conclusions: Despite similar clinical features at diagnosis, AS-eligible patients with similar clinical variables have significantly different outcomes and risk of APF due to molecular heterogeneity. Prognostic gene expression signatures such as the Decipher genomic classifier as well as PTEN loss and activated CD4 activity measured at diagnosis are associated with APF among AS eligible patients. Clinical trials within AS populations should consider utility of genomic signatures in patient selection.

Cell cycle progression score improves risk stratification in prostate cancer patients with adverse pathology after radical prostatectomy

Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy

Preoperative PROSTATE scoring system: a potential predictive tool for the risk of biochemical recurrence after radical prostatectomy.

PD42-10 PROGNOSTIC VALUE OF CELL CYCLE PROGRESSION SCORE IN PROSTATE CANCER PATIENTS WITH LOCALLY ADVERSE PATHOLOGY AFTER RADICAL PROSTATECTOMY: IMPLICATIONS FOR TREATMENT GUIDANCE

National Comprehensive Cancer Network (NCCN) Risk Classification in Predicting Biochemical Recurrence after Radical Prostatectomy: a Retrospective Cohort Study in Chinese Prostate Cancer Patients

Addition of cribriform pattern 4 and intraductal prostatic carcinoma into the CAPRA-S tool improves post-radical prostatectomy patient stratification in a multi-institutional cohort

Cmar_a_196286 6521..6529

Preoperative Predictors of Biochemical Recurrence-Free Survival in High-Risk Prostate Cancer Following Radical Prostatectomy

Validation of the Combined Clinical Cell-Cycle Risk Score to Prognosticate Early Prostate Cancer Metastasis From Biopsy Specimens and Comparison With Other Routinely Used Risk Classifiers

Management of prostate cancer patients with locally adverse pathologic features after radical prostatectomy: feasibility of active surveillance for cases with Gleason grade 3 + 4 = 7

Prognostic Significance of Modified Gleason Scoring System after Radical Prostatectomy

Association of transcriptomic biomarkers with adverse pathologic features at radical prostatectomy among active surveillance eligible men.

Predictive Factors Associated with Differential Pathologic Response to Neoadjuvant Chemohormonal Therapy in High-Risk Localized Prostate Cancer.

Combined Analysis of CRMP4 Methylation Levels and CAPRA-S Score Predicts Metastasis and Outcomes in Prostate Cancer Patients

Prediction of Biochemical Recurrence After Radical Prostatectomy Based on Preoperative 68Ga-PSMA-11 PET/CT

Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification

Effect of genetic variants in cell adhesion pathways on the biochemical recurrence in prostate cancer patients with radical prostatectomy

Outcome Comparison of Radical Prostatectomy Versus Seed Brachytherapy for Clinically Localized Prostate Cancer Using Two Biochemical Recurrence Definitions

Perioperative Change of Circulating Tumor Cells in Cytoreductive Radical Prostatectomy for Oligometastatic Hormone-Sensitive Prostate Cancer: the Preliminary Safety Evidence from Long-Term Oncologic Outcomes

Metabolic Syndrome and Its Components Predict the Biochemical Recurrence and Adverse Pathological Features of Patients Following Radical Prostatectomy: a Propensity Score Matching Study

The association of HER-2 expression with clinicopathological characteristics and clinical outcomes in patients with localized prostate cancer after radical prostatectomy